A shocking new study reveals that a condition that can lead to limb amputation is far more prevalent and deadly than ...

For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

"I shouldn't need a Rosetta Stone to understand your notes." -- Prashant Tailor, MD, of the University of California Los ...

Other symptoms may mimic signs of poor circulation like pins and needles, cold extremities, pale or blue skin, muscle ...